-
2023-504999-25-00
5
2023-07-14
Acute Myeloid Leukemia
-
2024-517666-41-00
5
2023-03-13
Prostate Cancer
-
2023-508389-13-00
5
2022-11-08
Combined endpoint of all-cause mortality, kidney failure, and hospital
-
2023-503442-30-00
5
2022-10-14
Multiple Myeloma
-
2024-511201-32-00
5
2022-06-13
Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
-
2023-507029-40-00
5
2022-05-09
Genetic carriers of dilated cardiomyopathy causing variants
-
2023-506891-28-00
5
2022-05-02
The target population of interest in this study is participants with l
-
2024-512726-28-00
6
2022-02-14
peritoneal metastases of colorectal cancer
-
2023-508963-58-00
4
2022-01-31
Symptomatic hypertrophic cardiomyopathy (HCM)
-
2023-508002-20-00
7
2021-10-21
advanced, solid, relapsed tumors / advanced tumors: human lymphomas /
-
2024-515273-10-00
7
2021-10-19
Relapsed or refractory Multiple Myeloma (r/r MM)
-
2024-516330-35-00
5
2021-09-29
Non-Small Cell Lung Cancer
-
2023-509321-50-00
5
2021-04-15
HER2-POSITIVE EARLY BREAST CANCER
-
2024-515063-66-00
4
2021-03-30
Early stage classical Hodgkin Lymphoma (cHL) without bulky lesions and
-
2024-512671-12-00
10
2021-03-05
Unresectable head and neck squamous cell carcinoma, metastatic head an
-
2022-501050-11-01
10
2020-07-13
Acute Lymphoblastic Leukaemia
-
2023-506546-23-00
5
2020-05-20
Acute myeloid leukemia
-
2023-508101-24-00
5
2019-08-01
Lymphoblastic lymphoma
-
2023-504201-36-00
10
2018-12-21
Defined by parent protocol. The study will enroll all adult and paedia
-
2022-501254-10-00
5
2018-08-24
Advanced tumors
-
2024-516110-38-00
5
2018-03-06
Hepatoblastoma and Hepatocellular Carcinoma
-
2024-512222-28-00
10
2015-06-02
Newly diagnosed with an intracranial or spinal ependymoma (all WHO gra
-
2024-516078-31-00
10
2015-05-05
Recurrent and Primary Refractory Ewing Sarcoma
-
2024-518254-16-00
5
2013-03-01
Acute Myeloid Leukemia (Pediatric 0-18 years)